Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

BACKGROUND: Immune checkpoint inhibition has been shown to have limited efficacy in patients with metastatic prostate cancer. Prostate cancers that harbor certain homologous recombination (HR) DNA repair gene mutations, inactivating CDK12 mutations or have underlying mismatch repair deficiency may b...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Prostate
Prif Awduron: Markowski, Mark C., Shenderov, Eugene, Eisenberger, Mario A., Kachhap, Sushant, Pardoll, Drew M., Denmeade, Samuel R., Antonarakis, Emmanuel S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7585736/
https://ncbi.nlm.nih.gov/pubmed/31972048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23955
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg